LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

NCT01523587 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

795

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: afatinib
DRUG: erlotinib

Sponsor

Boehringer Ingelheim